Gilead Sciences Expands Access to Experimental COVID-19 Treatment
An experimental treatment could become easier to get a hold of for hospitals with increasing numbers of COVID-19 patients. Gilead Sciences, (NASDAQ: GILD) a biopharmaceutical company, has already started ramping up approvals of applications for emergency use of an experimental coronavirus treatment called remdesivir.
The Food and Drug Administration (FDA) already has an expanded access program for experimental drugs that's more commonly known as the "compassionate use" program. Unfortunately, the compassionate use program isn't set up to handle a flood of requests that have been growing exponentially.
Image source: Getty Images.
Source Fool.com
